Results 241 to 248 of about 43,190 (248)
Some of the next articles are maybe not open access.

Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation

Annals of Internal Medicine, 2022
BACKGROUND Current guidelines recommend using direct oral anticoagulants (DOACs) over warfarin in patients with atrial fibrillation (AF), but head-to-head trial data do not exist to guide the choice of DOAC.
W. Lau   +12 more
semanticscholar   +1 more source

Rivaroxaban Is Associated With Higher Rates of Gastrointestinal Bleeding Than Other Direct Oral Anticoagulants

Annals of Internal Medicine, 2021
BACKGROUND Gastrointestinal bleeding (GIB) rates for direct oral anticoagulants (DOACs) and warfarin have been extensively compared. However, population-based studies comparing GIB rates among different DOACs are limited.
A. B. Ingason   +9 more
semanticscholar   +1 more source

Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data

Annals of Internal Medicine, 2021
BACKGROUND Apixaban and rivaroxaban are replacing vitamin K antagonists for the treatment of venous thromboembolism (VTE) in adults; however, head-to-head comparisons remain limited. OBJECTIVE To assess the effectiveness and safety of apixaban compared
G. Dawwas   +3 more
semanticscholar   +1 more source

Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome

Annals of Internal Medicine, 2019
Antiphospholipid antibody syndrome (APS) is an acquired thrombophilic disorder in which vascular thrombosis (venous or arterial) and pregnancy losses may occur in the presence of persistent antiphospholipid antibodies (aPLs) (14).
J. Ordi‐Ros   +10 more
semanticscholar   +1 more source

Oral rivaroxaban for symptomatic venous thromboembolism.

New England Journal of Medicine, 2011
The members of the writing committee (Rupert Bauersachs, M.D., Scott D. Berkowitz, M.D., Benjamin Brenner, M.D., Harry R. Buller, M.D., Hervé Decousus, M.D., Alex S. Gallus, M.D., Anthonie W. Lensing, M.D., Frank Misselwitz, M.D., Martin H.
G. Landman, R. Gans
semanticscholar   +1 more source

Rivaroxaban versus Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial.

Chest, 2021
B. Planquette   +24 more
semanticscholar   +1 more source

The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding

Journal of Thrombosis and Thrombolysis, 2020
S. Hanigan   +4 more
semanticscholar   +1 more source

Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.

The Lancet, 2017
S. Connolly   +499 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy